Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS44042872HTLV-1ENSG00000142192.22protein_codingAPPNoNo351A0A0A0MRG2
E9PG40
P05067
TVIS44042875HTLV-1ENSG00000142192.22protein_codingAPPNoNo351A0A0A0MRG2
E9PG40
P05067
TVIS44035325HTLV-1ENSG00000142192.22protein_codingAPPNoNo351A0A0A0MRG2
E9PG40
P05067
TVIS44051683HTLV-1ENSG00000142192.22protein_codingAPPNoNo351A0A0A0MRG2
E9PG40
P05067
TCGA Plot Options
Drug Information
GeneAPP
DrugBank IDDB12034
Drug NameGantenerumab
Target IDBE0003392
UniProt IDP05067
Regulation Typeantagonist
PubMed IDs21955818; 21987394
CitationsBohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF, Rothe C, Urban M, Bardroff M, Winter M, Nordstedt C, Loetscher H: Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis. 2012;28(1):49-69. doi: 10.3233/JAD-2011-110977.@@Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, Loetscher H, Santarelli L: Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012 Feb;69(2):198-207. doi: 10.1001/archneurol.2011.1538. Epub 2011 Oct 10.
GroupsInvestigational
Direct ClassificationPeptides
SMILES
Pathways
PharmGKB
ChEMBL